Join our daily newsletter At The Bell to receive exclusive market insights
- ResApp Health (RAP) has teamed up with Phenix Health to integrate their health-centric smartphone apps
- Phenix Health is an online virtual clinic, while ResApp has developed a health app to detect respiratory diseases
- From the beginning of COVID-19, Phenix said it has seen a 30 per cent month-on-month increase in the number of consultations
- ResApp’s software will enhance Phenix’s virtual clinics
- ResApp is up 13 per cent on the market this morning, trading at 7.8¢ per share
ResApp Health (RAP) has teamed up with Phenix Health to integrate their smartphone apps.
Phenix Health is mobile clinic software developers and provides an online virtual health clinic, called telehealth.
ResApp has developed a respiratory health app, ResAppDx-EU.
ResAppDx-EU is a software application used by clinicians to diagnose the most common respiratory diseases. The software uses machine learning algorithms to analyse the patient.
Phenix CEO Dr Gillian Alexis says telehealth is emerging as a key tool in tackling the COVID-19 pandemic and the company is well-positioned to provide a valuable service to the Australian community.
Phenix provides video consultations to patients across Australia and, since the beginning of this crisis, it has seen a 30 per cent month-on-month increase in the number of consultations.
“Our virtual clinic can be accessed nationwide
through HealthEngine or directly via our downloadable app, and for patients
told to self-isolate for possible COVID-19,
these consultations are reimbursable under the MBS scheme (medicare benefits
scheme),” Gillian said.
“Phenix knows that implementing a telehealth service for patients must go beyond the limits of consumer video chat platforms like Skype which is why we are working with ResApp to bring their advanced diagnostic tool to our platform,” he added.
ResApp currently has a CE marking from the European Union and Therapeutics Goods Administration in Australia for the app. However, it was recently denied approval by the U.S. Food and Drug Administration.
ResApp CEO Tony Keating is excited to be working with Phenix to enhance its service.
“ResAppDx-EU offers the only solution to accurately diagnose respiratory conditions through telehealth and will provide telehealth clinicians with a remote testing capability to help manage the COVID-19 pandemic,” Tony told the market.
“By assisting general practitioners (GPs) to evaluate patient symptoms during a telehealth consultation, in particular, if an infection has reached the patient’s lungs, GPs will be better able to determine whether a patient should attend a hospital or clinic for additional care, conserving strained healthcare resources,” he added.
The companies will be working together for the next three months. During this time, ResApp and Phenix are negotiating a fee-per-test payment model using ResAppDx-EU on the Phenix App.
ResApp is up 13 per cent on the market this morning, trading at 7.8¢ per share at 11:10 am AEDT.
